Comera Life Sciences (CMRAW) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock CMRAW vs. AIMDW, ALVOW, ARAV, ACABW, and RNAShould you buy Comera Life Sciences stock or one of its competitors? MarketBeat compares Comera Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Comera Life Sciences include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. CMRAW vs. AIMDWCMRAW vs. ALVOWCMRAW vs. ARAVCMRAW vs. ACABWCMRAW vs. RNAHow does Comera Life Sciences compare to Ainos?Ainos (NASDAQ:AIMDW) and Comera Life Sciences (NASDAQ:CMRAW) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment. Does the media refer more to AIMDW or CMRAW? In the previous week, Ainos' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score. Company Overall Sentiment Ainos Neutral Comera Life Sciences Neutral Is AIMDW or CMRAW more profitable? Company Net Margins Return on Equity Return on Assets AinosN/A N/A N/A Comera Life Sciences N/A N/A N/A Which has higher valuation and earnings, AIMDW or CMRAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAinos$18.11KN/AN/AN/AN/AComera Life Sciences$1.00MN/AN/AN/AN/A SummaryComera Life Sciences beats Ainos on 1 of the 1 factors compared between the two stocks.How does Comera Life Sciences compare to Alvotech?Comera Life Sciences (NASDAQ:CMRAW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk. Does the media refer more to CMRAW or ALVOW? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Alvotech'saverage media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Alvotech Neutral Which has higher earnings and valuation, CMRAW or ALVOW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00MN/AN/AN/AN/AAlvotech$586.32MN/AN/AN/AN/A Is CMRAW or ALVOW more profitable? Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Alvotech N/A N/A N/A SummaryAlvotech beats Comera Life Sciences on 1 of the 1 factors compared between the two stocks.How does Comera Life Sciences compare to Aravive?Comera Life Sciences (NASDAQ:CMRAW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings. Does the media refer more to CMRAW or ARAV? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Aravive Neutral Is CMRAW or ARAV more profitable? Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Aravive N/A N/A N/A Which has better valuation & earnings, CMRAW or ARAV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00MN/AN/AN/AN/AAraviveN/AN/AN/A-$0.90N/A Do institutionals & insiders hold more shares of CMRAW or ARAV? 35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryAravive beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.How does Comera Life Sciences compare to Atlantic Coastal Acquisition Corp. II?Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Comera Life Sciences (NASDAQ:CMRAW) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Is ACABW or CMRAW more profitable? Company Net Margins Return on Equity Return on Assets Atlantic Coastal Acquisition Corp. IIN/A N/A N/A Comera Life Sciences N/A N/A N/A Which has stronger valuation & earnings, ACABW or CMRAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AComera Life Sciences$1.00MN/AN/AN/AN/A Does the media favor ACABW or CMRAW? In the previous week, Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score. Company Overall Sentiment Atlantic Coastal Acquisition Corp. II Neutral Comera Life Sciences Neutral SummaryComera Life Sciences beats Atlantic Coastal Acquisition Corp. II on 1 of the 1 factors compared between the two stocks.How does Comera Life Sciences compare to Avidity Biosciences?Comera Life Sciences (NASDAQ:CMRAW) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Does the media prefer CMRAW or RNA? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Avidity Biosciences'average media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Avidity Biosciences Neutral Do analysts prefer CMRAW or RNA? Avidity Biosciences has a consensus price target of $69.42, suggesting a potential upside of 430.34%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Comera Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Comera Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.37 Is CMRAW or RNA more profitable? Comera Life Sciences has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Comera Life Sciences' return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Avidity Biosciences -3,650.39%-44.92%-39.57% Which has stronger earnings & valuation, CMRAW or RNA? Comera Life Sciences has higher earnings, but lower revenue than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00MN/AN/AN/AN/AAvidity Biosciences$36.68M6.10-$322.30MN/AN/A SummaryAvidity Biosciences beats Comera Life Sciences on 5 of the 8 factors compared between the two stocks. Get Comera Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRAW vs. The Competition ExportMetricComera Life SciencesBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$477.13M$6.45B$12.34BDividend YieldN/A3.87%2.76%5.28%P/E RatioN/A3.8121.2225.65Price / SalesN/A7,288.62553.9286.28Price / CashN/A13.1343.4956.67Price / BookN/A84.7810.377.14Net IncomeN/A-$96.07M$3.57B$335.98M Comera Life Sciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRAWComera Life SciencesN/AN/AN/AN/A$0.00$1.00MN/A2AIMDWAinosN/A$0.08+11.8%N/A-71.2%$0.00$18.11KN/A40Positive NewsGap UpALVOWAlvotechN/A$0.20flatN/A-89.5%$0.00$586.32MN/A4Positive NewsGap UpARAVAraviveN/A$0.04flatN/AN/A$0.00N/AN/A20High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.00flatN/A-77.3%$0.00N/AN/A15 Related Companies and Tools Related Companies AIMDW Alternatives ALVOW Alternatives ARAV Alternatives ACABW Alternatives RNA Alternatives BFRIW Alternatives CELUW Alternatives CINGW Alternatives DRMAW Alternatives ENGNW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMRAW) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
